Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 45

Results For "research"

2523 News Found

Fredun Pharmaceuticals launches India's first pure Jain dog biscuit
News | October 14, 2025

Fredun Pharmaceuticals launches India's first pure Jain dog biscuit

This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem


AbbVie showcases breakthrough ADC hard-to-treat cancers data at ESMO 2025
Clinical Trials | October 14, 2025

AbbVie showcases breakthrough ADC hard-to-treat cancers data at ESMO 2025

New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers


Maverick Simulation installs 3D anatomage table at Safdarjung Hospital
Medical Device | October 14, 2025

Maverick Simulation installs 3D anatomage table at Safdarjung Hospital

The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world


Cadila launches allergy relief tablet Dlorfast-M
News | October 13, 2025

Cadila launches allergy relief tablet Dlorfast-M

Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response


Lupin to present Phase 1 Data on STING agonist at the ESMO Congress 2025
Clinical Trials | October 13, 2025

Lupin to present Phase 1 Data on STING agonist at the ESMO Congress 2025

The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors


Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio
News | October 12, 2025

Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases


Novo Nordisk to acquire Akero Therapeutics for $5.2 billion
News | October 12, 2025

Novo Nordisk to acquire Akero Therapeutics for $5.2 billion

Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases


Merck unveils new HIV treatment and prevention data at EACS 2025
R&D | October 12, 2025

Merck unveils new HIV treatment and prevention data at EACS 2025

Merck will showcase results in innovative solutions in HIV treatment and prevention


Merck advances cancer innovation by expanding role of Keytruda across new tumor
R&D | October 11, 2025

Merck advances cancer innovation by expanding role of Keytruda across new tumor

The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025